<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="25779">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02771158</url>
  </required_header>
  <id_info>
    <org_study_id>temp-1187</org_study_id>
    <nct_id>NCT02771158</nct_id>
  </id_info>
  <brief_title>Midodrine During Recovery From Septic Shock</brief_title>
  <official_title>A Randomized Controlled Trial of Midodrine During Recovery Phase From Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwell Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwell Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether midodrine administration decreases
      duration of intravenous vasopressors and intensive care unit length of stay for patients in
      septic shock.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>duration of intravenous vasopressors</measure>
    <time_frame>from enrollment until discontinuation of intravenous vasopressors, expected to be 3-5 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>intensive care unit length of stay</measure>
    <time_frame>from enrollment until eligible for discharge from intensive care unit, expected to be 4-7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>re-institution of intravenous vasopressor</measure>
    <time_frame>from enrollment until hospital discharge, expected to be up to 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospital length of stay</measure>
    <time_frame>from enrollment until hospital discharge, expected to be up to 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>from enrollment until hospital discharge, expected to be up to 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>midodrine side effects requiring discontinuation</measure>
    <time_frame>from enrollment until hospital discharge, expected to be up to 30 days</time_frame>
    <description>including supine hypertension and bradycardia</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Hypotension</condition>
  <condition>Shock, Septic</condition>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>midodrine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>randomization to midodrine 20 mg every 8 hours to be increased to a maximum of 40 mg every 8 hours until intravenous vasopressor discontinuation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>randomization to placebo control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midodrine</intervention_name>
    <description>midodrine is metabolized to an active metabolite, desglymidodrine, which is an alpha adrenergic antagonist that causes vasoconstriction of both venous and arterial vasculature, thereby increasing blood pressure</description>
    <arm_group_label>midodrine</arm_group_label>
    <other_name>proamatine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo will be administered to double blind the study</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  admitted to intensive care unit

          -  diagnosis of septic shock on intravenous vasopressors

          -  stable/decreasing doses of intravenous vasopressors

          -  stable/improving organ function

        Exclusion Criteria:

          -  allergy to midodrine

          -  multiple intravenous vasopressors

          -  increasing intravenous vasopressor requirements

          -  worsening organ dysfunction

          -  severe bradycardia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <reference>
    <citation>Whitson MR, Mo E, Nabi T, Healy L, Koenig S, Narasimhan M, Mayo PH. Feasibility, Utility, and Safety of Midodrine During Recovery Phase From Septic Shock. Chest. 2016 Jun;149(6):1380-3. doi: 10.1016/j.chest.2016.02.657. Epub 2016 Mar 4.</citation>
    <PMID>26953217</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 7, 2016</lastchanged_date>
  <firstreceived_date>March 28, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwell Health</investigator_affiliation>
    <investigator_full_name>Micah Whitson</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>critical care</keyword>
  <keyword>shock, septic</keyword>
  <keyword>sepsis</keyword>
  <keyword>hypotension</keyword>
  <keyword>midodrine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Shock</mesh_term>
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Hypotension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Midodrine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
